2/5
05:03 am
stok
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
2/4
04:27 pm
stok
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
Medium
Report
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 [Yahoo! Finance]
2/4
04:01 pm
stok
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
1/27
02:22 pm
stok
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA [Yahoo! Finance]
Low
Report
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA [Yahoo! Finance]
1/27
02:05 pm
stok
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
Low
Report
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
1/16
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
1/15
09:15 am
stok
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
Medium
Report
Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]
1/12
09:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Wedbush from $32.00 to $36.00. They now have an "outperform" rating on the stock.
1/11
02:13 pm
stok
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
Medium
Report
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome [Yahoo! Finance]
1/11
02:00 pm
stok
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
Medium
Report
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
1/6
04:01 pm
stok
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/5
08:33 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at Chardan Capital from $24.00 to $35.00. They now have a "buy" rating on the stock.
1/5
08:02 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $36.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $36.00 price target on by analysts at Canaccord Genuity Group Inc.. They now have a "buy" rating on the stock.
1/5
07:17 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $35.00 price target on by analysts at Loop Capital.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $35.00 price target on by analysts at Loop Capital.
12/16
04:01 pm
stok
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Low
Report
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
12/15
10:58 am
stok
Stoke Therapeutics (NASDAQ:STOK) was given a new $50.00 price target on by analysts at UBS Group AG.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) was given a new $50.00 price target on by analysts at UBS Group AG.
12/15
09:04 am
stok
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at HC Wainwright from $35.00 to $50.00. They now have a "buy" rating on the stock.
Low
Report
Stoke Therapeutics (NASDAQ:STOK) had its price target raised by analysts at HC Wainwright from $35.00 to $50.00. They now have a "buy" rating on the stock.
12/10
09:32 pm
stok
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? [Yahoo! Finance]
Medium
Report
Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell? [Yahoo! Finance]
12/6
07:29 pm
stok
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? [Yahoo! Finance]
Medium
Report
Is New Neurology Data And Partnerships Altering The Investment Case For Biogen (BIIB)? [Yahoo! Finance]
12/5
09:40 am
stok
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
Low
Report
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting [Yahoo! Finance]
12/5
09:00 am
stok
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Low
Report
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
12/4
05:12 pm
stok
Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]
Low
Report
Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]
12/1
07:30 am
stok
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Low
Report
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
11/28
10:18 am
stok
Biotechs Are On A Big Run, And Two Stocks Have Buy Points [Yahoo! Finance]
Low
Report
Biotechs Are On A Big Run, And Two Stocks Have Buy Points [Yahoo! Finance]
11/21
05:31 am
stok
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Medium
Report
Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.